8-K: STERIS Exceeds Q2 Expectations, Boosts FY26 Outlook

STERIS plc reported strong fiscal 2026 second-quarter results, with total revenue up 10% and adjusted EPS increasing to $2.47, leading to an upward revision of its full-year financial guidance.

Summary

• Total revenue from continuing operations increased 10% to $1.5 billion in Q2 FY26, compared to $1.3 billion in Q2 FY25.
• Constant currency organic revenue growth from continuing operations was 9% for the second quarter.
• As reported diluted EPS from continuing operations rose to $1.94, up from $1.51 in the prior year.
• Adjusted diluted EPS increased to $2.47, compared to $2.14 in Q2 FY25.
• Net cash provided by operations for the first half of fiscal 2026 was $707.8 million, a significant increase from $554.4 million in the first half of fiscal 2025.
• Free cash flow for the first half of fiscal 2026 was $527.7 million, up from $344.5 million in the prior year period.
• The company increased its fiscal 2026 outlook for constant currency organic revenue growth to 7-8% (from 6-7%), adjusted EPS to $10.15-$10.30 (from $9.90-$10.15), and free cash flow to approximately $850 million (from $820 million).

Sentiment

Score: 9

Explanation: The company delivered strong financial results for the second quarter, exceeding expectations across key metrics like revenue and EPS. The subsequent increase in the full fiscal year outlook for organic revenue, adjusted EPS, and free cash flow, despite headwinds like tariffs and inflation, indicates robust operational performance and positive momentum.

Positives

• Total revenue from continuing operations increased 10% to $1.5 billion.
• Constant currency organic revenue growth was strong at 9%.
• As reported EPS from continuing operations increased to $1.94 from $1.51.
• Adjusted EPS increased to $2.47 from $2.14.
• Healthcare segment revenue grew 9% with 13% service revenue and 10% consumable revenue improvement.
• Applied Sterilization Technologies (AST) revenue increased 10%, driven by 13% service revenue growth.
• Life Sciences revenue increased 13%, with 39% growth in capital equipment revenue.
• Net cash provided by operations for the first half of fiscal 2026 significantly increased to $707.8 million from $554.4 million.
• Free cash flow for the first half of fiscal 2026 increased to $527.7 million from $344.5 million, driven by earnings growth and working capital improvements.
• Fiscal 2026 outlook for constant currency organic revenue, adjusted EPS, and free cash flow were all increased.
• Healthcare backlog increased to $427.5 million from $405.3 million.
• Life Sciences backlog increased to $113.7 million from $75.6 million.

Negatives

• AST segment experienced a 76% decline in capital equipment revenue.
• Healthcare operating income was partially offset by tariff costs and inflation.
• Life Sciences operating income was partially offset by tariff costs and inflation.
• The fiscal 2026 outlook includes a negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million.
• The expected effective tax rate for fiscal 2026 increased to approximately 24% from 23.5%.

Risks

• Operating costs, pressure on pricing (including from inflation), customer loss, and business disruption could be greater than expected, leading to erosion of profit margins.
• Difficulties in successfully integrating acquired businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs.
• Changes in tax laws or interpretations, or the adoption of certain income tax treaties, could increase consolidated tax liabilities, including changes that would treat STERIS as a domestic corporation for U.S. federal tax purposes, or tariffs and/or other trade barriers.
• Compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of pending or threatened litigation (e.g., ethylene oxide litigation), may delay, limit, or prevent new product/service introductions, impact production/supply/marketing, result in uncovered costs, or otherwise affect performance.
• Potential for international unrest, military conflicts, economic downturn, and effects of currency fluctuations.
• Possibility of delays in receipt of orders, order cancellations, or delays in the manufacture or shipment of ordered products.
• Anticipated growth, performance, or other results may not be achieved, or timing, execution, impairments, or other issues may adversely impact performance.
• Impact on operations from legislation, regulations, or orders implemented by the U.S. administration or Congress, or responses by non-U.S. governments.
• Anticipated financial results, productivity improvements, cost savings, growth synergies, and other benefits of acquisitions, restructuring efforts, and divestitures may not be realized or may be less than anticipated.
• Level of indebtedness limiting financial flexibility or increasing future borrowing costs.
• Effects of changes in credit availability and pricing, and the ability of STERIS and its customers/suppliers to adequately access credit markets.
• Increasing competition within the industry, which may exert pressure on pricing strategy or lead to decreasing demand.
• Labor-related issues such as strikes, unsuccessful union negotiations, and other workforce disruptions.
• Economic downturns and recessions, which could negatively impact business by reducing consumer and customer spending.

Future Outlook

STERIS plc has increased its fiscal 2026 outlook, now expecting constant currency organic revenue from continuing operations to grow 7-8% (up from 6-7%), adjusted earnings per diluted share to be in the range of $10.15 to $10.30 (up from $9.90 to $10.15), and free cash flow to be approximately $850 million (up from $820 million). The company anticipates an unchanged 8-9% increase in as reported revenue and capital expenditures of approximately $375 million, while foreign currency impact expectations are reduced to 100 basis points. A negative tariff impact of $45 million on pre-tax profit and an effective tax rate of approximately 24% are also included in the outlook.

Management Comments

• "We are pleased with our performance in the second quarter."
• "Our performance exceeded expectations and margins improved nicely, despite several headwinds."
• "As a result, we are increasing our outlook for fiscal 2026."

Industry Context

STERIS operates in the healthcare and life sciences sectors, providing infection prevention products and services. The strong performance, particularly in service and consumable revenues across Healthcare and AST segments, suggests robust demand for essential medical and sterilization services. The growth in Life Sciences capital equipment also indicates continued investment in research and manufacturing capabilities within the pharmaceutical and biotech industries. The company's ability to increase its outlook despite 'several headwinds' (likely referring to inflation and tariffs mentioned) suggests strong underlying market demand and effective operational management in a challenging global economic environment.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. However, the reported 9% constant currency organic revenue growth and increased EPS and free cash flow outlook suggest a strong performance relative to general market expectations, especially given the mentioned headwinds of tariffs and inflation that are common industry challenges.

Legal Proceedings

• The cautionary statement mentions the potential impact of pending or threatened litigation, including the ethylene oxide litigation, which may delay, limit, or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, or result in uncovered costs.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, higher free cash flow, and an improved fiscal year outlook, potentially leading to increased share value and continued dividends (cash dividends declared per share ordinary outstanding increased to $0.63 from $0.57).
• Employees: Positive impact from strong company performance, which can lead to job security and potential for growth, though restructuring efforts were mentioned in the past.
• Customers: Continued provision of innovative healthcare and life science products and services, supporting patient care and infection prevention.
• Suppliers: Continued business relationships, though the company's focus on productivity and managing costs (like tariffs) might influence negotiations.
• Creditors: Improved financial health and free cash flow enhance the company's ability to meet debt obligations.

Next Steps

• STERIS management will host a conference call on November 6, 2025, at 9:00 a.m. ET to discuss the results.

Key Dates

Recommendation

The company has demonstrated exceptional performance in its fiscal second quarter, significantly exceeding prior expectations and delivering robust growth across all key segments. The upward revision of the full fiscal year guidance for constant currency organic revenue, adjusted EPS, and free cash flow signals strong underlying business momentum and effective management in navigating economic headwinds such as tariffs and inflation. The substantial increase in free cash flow and backlog further strengthens the company's financial position. Given the consistent outperformance and positive outlook, STERIS plc presents a compelling investment opportunity for sustained growth.

Keywords

STERIS, STE, Financial Results, Earnings, Q2 2026, Fiscal 2026, Revenue Growth, EPS, Free Cash Flow, Healthcare, Applied Sterilization Technologies, Life Sciences, Outlook Increase, Infection Prevention, Medical Devices, Pharmaceutical Services